Development Of A New Specific Immunosuppressive Monoclonal Antibody To Advance Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$736,300.00
Summary
Current nonspecific immunosuppressive agents compromise post transplant protective responses, including the anti-tumour effect of a bone marrow transplant. We have developed an antibody (3C12C), that targets CD83 on activated dendritic cells as a new, more specific, immunosuppressive strategy. We will work with our commercial partner to develop the patented antibody as a new imunosuppressive agent, which retains anti-viral and anti-cancer responses. This would be a major advance for patients.
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.
Organ transplantation is the measure of last resort for patients with organ failure. While this is a life-saving procedure, the long-term survival of transplant recipients depends on maintaining the new organ without rejecting it. The proposed research will create novel test systems that allow both patients and clinicians to monitor the concentration of the drugs required to suppress organ rejection. Such a test will reduce the cost of treatment and increase the long term survival of patients.
Manufacture And Testing Of Next Generation Orthopaedic Implants Harnessing Periosteum's Regenerative Power
Funder
National Health and Medical Research Council
Funding Amount
$508,314.00
Summary
Tissue defects, e.g. due to trauma or tumor removal, are too large to heal without reconstructive surgery. Complications associated with defect repair may diminish the patient's quality of life and productivity, posing significant medical and psychosocial costs. Here we propose a plan to define technical specifications for next generation, "smart" orthopaedic implants that deliver cells and the signals they need to build new tissue using nature's paradigms.